

VERSION*

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61F 2/00	A1	(11) International Publication Number: WO 98/56311 (43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: PCT/US98/12368		(74) Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).
(22) International Filing Date: 12 June 1998 (12.06.98)		
(30) Priority Data: 08/873,444 12 June 1997 (12.06.97) US 08/928,946 12 September 1997 (12.09.97) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 08/873,444 (CIP) Filed on 12 June 1997 (12.06.97) US 08/928,946 (CIP) Filed on 12 September 1997 (12.09.97)		
(71) Applicant (for all designated States except US): UROMEDICA, INC. [US/US]; Suite 116A, 11900 Wayzata Boulevard, Minnetonka, MN 55305 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(72) Inventors; and (75) Inventors/Applicants (for US only): COOK, Timothy, C. [US/US]; 16255 Holdridge Road West, Wayzata, MN 55391 (US). BURTON, John, H. [US/US]; 15460 Wing Lake Drive, Minnetonka, MN 55345 (US).		

(54) Title: ADJUSTABLE IMPLANTABLE GENITOURINARY DEVICE



(57) Abstract

An implantable medical device and method for adjustably restricting a selected body lumen such as a urethra or ureter of a patient to treat urinary incontinence or ureteral reflux. The device includes an adjustable, self-sealing element having a continuous wall, including an inner surface defining a chamber. The adjustable element expands or contracts due to fluid volume introduced in the chamber for restricting a body lumen. After being implanted into a patient, the size of the adjustable element is altered by first locating the adjustable element implanted adjacent the body lumen, and then establishing fluid communication with the adjustable element. The volume of the adjustable element is then adjusted by either introducing or removing volume from the chamber of the adjustable element.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finnland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ADJUSTABLE IMPLANTABLE GENITOURINARY DEVICE

Field of the Invention

The invention relates generally to implantable medical devices
5 and in particular to implantable medical devices for treating urinary
incontinence.

Background of the Invention

Various implantable devices, such as distensible medical devices,
are known in which the distensible medical devices are implanted into the tissue
10 of a human to treat urinary incontinence. These devices have typically relied
upon restricting or constricting the urethra of the patient to maintain continence.

U.S. Patent 4,733,393 to Haber et al. is an attempt at such a
proposed device. U.S. Patent 4,733,393 relates to a hypodermically implantable
genitourinary prosthesis which provides an extensible, inflatable tissue
15 expanding membrane to be located in proximal urethral tissue to add bulk to
these tissues for overcoming urinary incontinence by localized increase in tissue
volume.

U.S. Patent 4,802,479 to Haber et al. is an attempt at an instrument
for dispensing and delivering material to an inflatable membrane of a
20 genitourinary prosthesis within the tissues of a patient for overcoming urinary
incontinence. U.S. Patent 4,832,680 to Haber et al. relates to an apparatus for
hypodermically implanting a genitourinary prosthesis comprising an extensible
containment membrane for retaining a fluid or particulate matter which is
injected from an external source.

25 U.S. Patent 5,304,123 to Atala et al. relates to a detachable
membrane catheter incorporated into an endoscopic instrument for implantation
into the suburethral region of a patient. Also, U.S. Patent 5,411,475 to Atala et
al. discusses a directly visualized method for deploying a detachable membrane
at a target site *in vivo*.

30 Once inflated, these devices maintain pressure on the urethra of the
patient in an attempt to assist with continence. However, these devices are prone
to being under or over inflated at time of implant, leading to undesirable

postoperative results. For example, if the devices are overinflated it may cause the urethra to be restricted too tightly, and the patient is at risk for retention, a condition where the patient cannot pass urine. Such a condition could lead to kidney damage, necessitating major corrective surgery or at minimum use of self-catheterization to empty the bladder on a regular basis thus increasing the risk of urinary tract infection.

Furthermore, once these devices have been implanted within the patient, the only means of removing them in the event of a postoperative problem or device malfunction is through major surgery. Additionally, once the device has been implanted into the patient there is the possibility of the device migrating back along the pathway created during its insertion, a problem which has been noted with prior art devices. Thus, an important medical need exists for an improved implantable device for treating urinary incontinence.

Summary of the Invention

The present invention provides an implantable device and a method for its use in restricting a body lumen. In one embodiment, the body lumen is a urethra, where the implantable device is used to coapt the urethra to assist the patient in urinary continence. The implantable medical device has the advantage of being adjustable both at the time of implantation and postoperatively. This postoperative adjustability of the implantable medical device allows a physician to regulate the amount of pressure applied to the urethra to ensure continence of the patient and to minimize iatrogenic effects.

In one embodiment of the invention, a patient's incontinence is treated by positioning one or more of the implantable devices adjacent to at least one side of a patient's urethra so as to adjust liquid flow resistance in the urethra. This is accomplished by using the implantable devices to coapt the patient's urethra so as to maintain a transverse cleft or slit structure of the collapsed urethra and thereby provide sufficient flow resistance to ensure continence, while still allowing the patient to consciously discharge urine when necessary.

The device according to one embodiment of the invention is intended to work immediately adjacent to the urethral wall of a patient to create an increase in urethral coaptation and flow resistance. In one embodiment, this

increase in urethral coaptation and flow resistance is due to the displacement of body tissue adjacent to the body lumen. However, in the prior art devices any tissue change which may occur postoperatively such as a reduction in tissue edema associated with the procedure may cause a reduction in clinical effect
5 because of the reduced coaptation and resistance after the swelling has subsided.

In one embodiment, the implantable device for treating urinary incontinence comprises an adjustable element having a continuous wall or membrane, where the wall includes an inner surface defining a chamber. The continuous wall is constructed of at least one material that is substantially self-sealing, and therefore, is able to withstand multiple punctures, for example from non-coring hypodermic needles, during postoperative adjustments of the
10 adjustable element.

In one embodiment, the continuous wall is constructed of a biocompatible resiliently elastomeric polymer or polymer blend of polyurethane, silicone, or the like. In an additional embodiment, the continuous wall of the
15 adjustable element has an outer surface generally defining a sphere. In yet another embodiment, the continuous wall has an outer surface generally defining an elongate body having semi-spherical end portions.

During the postoperative adjustments, the adjustable element is expanded or contracted (*i.e.*, the volume of the adjustable element is increased or decreased) due to fluid volume introduced into the chamber. In one embodiment, fluid volume is introduced into the chamber through a hollow non-coring needle, such as a hypodermic needle, inserted through the wall of the
20 adjustable element. The self-sealing ability of the wall allows for such
25 adjustments by needles during one or more postoperative occasions without compromising the pressure retaining ability of the wall of the adjustable element.

In an additional embodiment, the implantable device includes one or more reinforcing structures positioned between the inner surface and an outer surface of the continuous wall. In one embodiment, woven or layered fibers of
30 polyester, nylon, polypropylene, polytetrafluoroethylene (such as TEFLON) or other polymers having a high durometer measure or high modulus constitute the reinforcing structures. The reinforcing structures help to maintain structural

integrity and the shape of the adjustable element during the initial inflation and any postoperative adjustments made thereafter.

In an additional embodiment, the continuous wall of the adjustable element has a porous polymer structure that allows the movement of water between the outer surface and the inner surface. A hydrophilic polymer is substantially encapsulated in the chamber, where the hydrophilic polymer absorbs water to expand the implantable device. Once implanted within a patient, the volume of the adjustable element is altered (*i.e.*, expanded or contracted) during implantation and/or postoperatively by introducing or removing the hydrophilic polymer from the chamber. In one embodiment, the hydrophilic polymer is hyaluronic acid, polyvinylpyrrolidone, polyethylene glycol, or carboxy methyl cellulose.

In an additional embodiment, the implantable medical device includes a tubular elongate body, such as a conduit, connected to and sealed to the adjustable element. The tubular elongate body includes a first interior passageway extending longitudinally in the tubular elongate body from a first port at the proximal end to a second port in fluid communication with the chamber of the implantable device for adjustably expanding or contracting the adjustable element by applied fluid volume introduced through the first port. Expansion of the adjustable element is accomplished by delivering a fluid material into the first port of the implantable device remote from the adjustable element, but near the patient's skin, thus enabling post-operative adjustment with minimal surgical invasiveness.

The tubular elongate body further includes a second interior passageway extending longitudinally in the tubular elongate body from a proximal opening through the peripheral surface positioned between the proximal and the distal end to a distal opening through the distal end of the tubular elongate body. This second interior passageway is of sufficient diameter to receive an elongate probe member adapted for delivery of the implantable medical device to the desired site in the body tissue of a patient. In one embodiment, the elongate probe member is a solid stylet. In one embodiment, the elongate probe member is an obturator. Alternatively, the elongate probe

member includes a flexible guidewire which has been initially delivered into the body tissue through a separate hollow stiff probe that has been inserted to the desired location in the body tissue.

This embodiment of the implantable device also includes a rear port element coupled to the proximal end of the tubular elongate body. The rear port element including a cavity in fluid communication with the first port of the first interior passageway. An elastic septum is included on the rear port element, and is retained in the rear port element by a clamp ring located around the rear port element.

An improvement provided by one embodiment of the present invention resides in the ability to access the implanted rear port element located close to the surface of the patient's skin to adjustably restrict the urethra. This is accomplished by controlling the volume of a fluid, such as a flowable material, in the adjustable element after it has been implanted in the patient. Suitable flowable materials for introduction into the expandable membrane include a saline liquid, a flowable gel, or a slurry of small particles such as silicone in a fluid carrier. Moreover, the flowable material may be made radiopaque to facilitate fluoroscopic visualization for postoperative inspection.

The post implantation, or postoperative, urethral restriction is realized by the adjustable element acting on tissue adjacent to the walls of the urethral lumen and forcefully closing the urethral lumen. Voiding of urine from the bladder only occurs when the intravesical pressure overcomes the resistance established by the adjustable element.

An important feature of the implantable device of the present invention relates to the adjustable element or membrane which is accessible for subsequent adjustment in volume through the rear port element located under a patient's skin, remotely from the adjustable element. Another important feature of the present invention over the prior art devices is the convenient *in vivo* postoperative adjustability of both pressure and size of the adjustable element.

30 Brief Description of the Drawings

In the drawings, where like numerals describe like components throughout the several views:

Figure 1 (A-D) is a schematic view of an adjustable element according to one embodiment of the present invention;

Figure 2 is a schematic cross-sectional view of the adjustable element of Figure 1;

5 Figure 3 is one embodiment of reinforcing structures within the continuous wall of the adjustable element;

Figure 4 is one embodiment of an implantable device according to the present invention;

10 Figure 5 is a longitudinal cross-sectional view of the implantable device of Figure 4;

Figure 6 is a cross-sectional view taken along line 6-6 of Figure 5;

Figure 7 is a schematic view of an adjustable element according to one embodiment of the present invention;

15 Figure 8 is a schematic cross-sectional view of the adjustable element of Figure 7;

Figure 9 is one embodiment of an elongate probe member inserted into body tissue to an implant location adjacent a body lumen of a patient prior to insertion of the implantable device;

20 Figure 10 is one embodiment of the implantable device placed over an elongate probe member and partially advanced to the desired location with the adjustable element being deflated;

Figure 11 is one embodiment of the implantable medical device implanted within the body tissue with the adjustable element expanded to cause the adjustable restriction of the body lumen;

25 Figure 12 is a partial view of one embodiment of the implantable medical device implanted within the body tissue;

Figure 13 is a cross-sectional view taken along line 13-13 of Figure 11;

30 Figure 14 is one embodiment of adjusting an implanted adjustable element; and

Figure 15 is one embodiment of adjusting an implanted adjustable element.

Detailed Description of the Invention

In the following detailed description, reference is made to the accompanying drawings which form a part hereof and in which is shown by way of illustration specific embodiments in which the invention may be practiced.

5 These embodiments are described in sufficient detail to enable those skilled in the art to practice and use the invention, and it is to be understood that other embodiments may be utilized and that logical, and structural changes may be made without departing from the spirit and scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense
10 and the scope of the present invention is defined by the appended claims and their equivalents.

In one embodiment, the present invention provides an adjustable implantable device which restricts urine from involuntarily escaping from the bladder, thus establishing continence for the patient. This adjustable component
15 can be done in a post-operative manner once the patient has resumed daily activity via an evaluation to determine what activities cause bladder stress and observable incontinence.

20 In Figures 1 (A-D) and 2 of the drawings, there is shown an implantable device 20 for restricting a body lumen. In one embodiment, the implantable device 20 is for treating ureteral reflux of a patient by implanting at least one of the implantable devices adjacent one or both ureteral orifices. In an alternative embodiment, the implantable device 20 is for treating urinary incontinence by implanting at least one of the implantable devices adjacent the urethra.

25 Implantable devices designed for treating urinary incontinence are typically referred to as a genitourinary prosthesis. Many designs for genitourinary prosthesis have been proposed. In one such proposed embodiment, genitourinary prosthesis are comprised of elastomeric, elliptoidally or spherically-shaped containment membranes which have an interior chamber designed to receive a measured supply of fluid to inflate the prosthesis. One such description of a genitourinary prosthesis is also provided in a co-pending U.S. Patent Application Serial No. 08/873,444, entitled "Implantable Device and

Method for Adjustably Restricting a Body Lumen" filed June 12, 1997, by Burton et al.

In one embodiment, the present invention provides an implantable device for adjustably restricting a body lumen, and is suitable for treating both male and female patients suffering from stress incontinence. In treating urinary incontinence, the prosthesis are delivered within the body to a location that is typically within the periurethral tissue and adjacent to the urethra to enable a patient to overcome urinary incontinence by means of increasing both localized tissue volume and passive occlusive pressure upon the urethral mucosa.

The prosthesis may be mounted on a hollow non-coring needle, such as a hypodermic needle, which is releasably connected to a fluid source, such as a syringe element. In order to facilitate inserting the prosthesis into position, the prosthesis is housed within a tubular body, such as a trocar tube, where the tubular body is designed to penetrate the tissues of the patient, thus allowing the proper placement of the prosthesis. Alternatively, the prosthesis could be mounted at or on a distal end of a trocar tube to allow for delivery of the prosthesis within the patient.

Once the prosthesis has been positioned within the body, it is inflated by infusing a measured supply of fluid volume, including fluid volume having particulate matter into the interior of the membrane of the prosthesis. Fluids suitable for infusing into the prosthesis include, but are not limited to, sterile saline solutions, polymer gels such as silicone gels or hydrogels of polyvinylpyrrolidone, polyethylene glycol, or carboxy methyl cellulose for example, high viscosity liquids such as hyaluronic acid, dextran, polyacrylic acid, or polyvinyl alcohol for example, or liquids that coagulate on contact with body fluids. The fluids also include fluids having a variety of particulate matter, and include, but are not limited to particles having a spherical shape, an elongate shape, or particles having a cross sectional star shape. Once the prosthesis has been inflated, the needle is withdrawn from the prosthesis and the tubular body is withdrawn from the body, leaving the inflated prosthesis in position.

Figures 1A and 2 shows one embodiment of an implantable device 20 for restricting a body lumen comprising an adjustable, self-sealing element

22, such as an expandable element, having a continuous wall 24. The continuous wall 24 includes an inner surface 26 defining a chamber 28. Furthermore, the continuous wall 24 is constructed of at least one material that is substantially self-sealing to allow for the adjustable element 22 to be expanded or contracted
5 due to fluid volume introduced into the chamber 28. In one embodiment, the continuous wall 24 itself is constructed of a self-sealing material. In an alternative embodiment, the inner surface 26 of the adjustable element 22 has a material that imparts a self-sealing ability to the adjustable element 22 such as crosslinked silicone gel, polyvinylpyrrolidone, or karaya gum for example.

10 Figures 1B-D show several embodiments of genitourinary prosthesis implanted in a patient. Figure 1B is one embodiment of positioning the adjustable element 22 of the present invention, where one adjustable element 22 is positioned adjacent a urethra 23 of the patient. In an alternative embodiment, Figure 1C shows two of the adjustable element 22 positioned
15 adjacent the urethra 23, where each of the adjustable element 22 are generally disposed on opposite sides of and in a similar plane perpendicular to the urethra 23. In an additional embodiment, Figure 1D shows two of the adjustable elements 22 positioned adjacent the urethra 23, where each of the adjustable elements 22 are generally disposed on opposite sides of the urethra 23, with each
20 of the adjustable elements 22 in generally a different plane perpendicular the urethra 23 to create at least two portions of the urethra having a coapted portion and leading to the urethra 23 having a tortious configuration. In an alternative embodiment, the adjustable element 22 is placed next to a ureteral orifice.

25 In one embodiment, the continuous wall 24 is intended and designed to be pierced by hollow non-coring needles on one or more occasions for adjusting the volume of the adjustable element during both the implanting of the adjustable element and during subsequent postoperative adjustment of the adjustable element. As such, the continuous wall 24 is constructed of a material that is tear-resistant and biocompatible. In one embodiment, the material is also substantially self-sealing during and after being pierced by a hollow non-coring needle to maintain fluid volume within the chamber 28 of the adjustable element.
30

In an additional embodiment, the adjustable element 22 has two or

more continuous walls 24, where the continuous walls 24 are arranged concentrically with one of two or more continuous walls 24 being within another continuous wall 24 (not shown). The two or more continuous walls 24 of the present embodiment are separated from each other due to the presence of fluid between the continuous walls 24. In one embodiment, the chambers created by each of the continuous walls 24 are filled with any combination of fluids described within this detailed description.

In one embodiment, the continuous wall is constructed of a biocompatible resiliently elastomeric polymer or polymer blend of polyurethane, silicone, or the like. In this embodiment, the continuous walls 24 stretch as the adjustable element 22 expands or contracts to a desired size. In an alternative embodiment, the continuous wall is constructed of a biocompatible non-resilient polymer or polymer blend of polyethylene, polytetrafluoroethylene, polystyrene, or polyetheretherketone (PEEK). In this embodiment, the continuous wall 24 of the adjustable element 22 expand to a predetermined shape. The adjustable element is formed into a variety of shapes. In one embodiment, the outer surface 32 of the continuous wall 24 generally defines a spherical shape. In an alternative embodiment, the outer surface 32 of the continuous wall 24 generally defines an elongate body having semi-spherical end portions. In one embodiment, a adjustable element 22 being constructed of a biocompatible resiliently elastomeric polymer or polymer blend typically retains the same general cross-sectional shape deflated as when inflated. In an alternative embodiment, when the adjustable element 22 is constructed of a biocompatible non-resilient elastomeric polymer or polymer blend the deflated adjustable element 22 typically has a configuration in which the continuous wall 24 has a folded structure which as the adjustable element 22 is inflated changes to take on a preformed cross-sectional shape and size and/or diameter.

Referring now to Figure 3, there is shown an embodiment of a portion of the continuous wall 24, where the continuous wall 24 further includes one or more reinforcing structures 30 positioned between the inner surface 26 and an outer surface 32 of the continuous wall 24. In one embodiment, the one or more reinforcing structures 30 are designed to support the structural integrity

of the continuous wall 24, helping to provide the substantially self-sealing nature of the adjustable element 22, and to assist in retaining particles within the chamber 28 of the adjustable element 22. In one embodiment, the one or more reinforcing structures 30 are fibers constructed from the group comprising one or 5 more of polyester, nylon, polypropylene, polytetrafluoroethylene (such as TEFLON) or other polymers having a high durometer measure or high modulus constitute the reinforcing structures.

In one embodiment, the fibers of the one or more reinforcing structures 30 form a mesh, such as when woven into a support structure that is 10 positioned between the inner surface 26 and the outer surface 32 of the continuous wall 24. In an additional embodiment, the fibers of the one or more reinforcing structures 30 are less elastic than the continuous wall 24, and the woven support structure has a loose weave configuration to allow for the support structure to expand or contract with the expansion and contraction of the 15 continuous wall 24 of the adjustable element 22.

In an alternative embodiment, the fibers of the one or more reinforcing structures 30 are substantially non-elastic and are arranged in a woven configuration, where the fibers have a kinked structure that allows them to expand or contract with the expansion and contraction of the continuous wall 20 24 of the adjustable element 22.

The one or more reinforcing structures 30 provide the adjustable element 22 with reinforced structural integrity and an increased ability to retain infused particles within the chamber 28 of the adjustable element 22. In one embodiment, the fibers of the one or more reinforcing structures 30 woven into the support structure provide a "rip-stop" function. As an example, the woven support structure allows for rip-stop protection from tears in the continuous wall 25 24 due to insertion and removal of hollow non-coring needles through the continuous wall 24. In an additional embodiment, the woven support structure prevents the migration of particle from the chamber 28, where the particles are used to inflate the adjustable element 22. In one embodiment, the particles are 30 prevented from migrating out of the chamber 28 due to the tightness of the weave of the support structure.

As previously mentioned, a variety of particulate matter is suitable for infusing into the chamber 28 of the adjustable element 22. The particulate matter is typically suspended in a carrier fluid, or lubricious fluid, however, this is not necessary. Examples of particulate matter shapes include collapsible hollow spheres or those having multiple projecting arms or structures from a central axis. In one embodiment, the structure of the particulate matter has a larger diameter than both the inner diameter of the hollow non-coring needle and the opening in the woven structure of the reinforcing structure 30. To inject the particulate matter into the chamber 28 of the adjustable element 22, the surface 5 of the particulate matter is physically distorted to allow it to pass through the inner diameter of the hollow non-coring needle, such as the hollow spheres collapsing or the projecting arms bending. Once the particulate matter has passed through the hollow non-coring needle, the particulate matter expands 10 back to a size greater than the hole created by the needle, thus making the device self sealing.

15

In an alternative embodiment, the particulate matter is an elongate body, such as a tubular elongate structure, such that the particulate matter can pass longitudinally through the hollow non-coring needle, but once inside the adjustable element 22 their random orientation would essentially prevent them 20 from passing back through any needle hole created by the hollow non-coring needle.

In an alternative embodiment, the inner diameter of the hollow non-coring needle is sufficient to pass the particulate matter, however the structure of the particulate matter has a larger diameter than the openings in the woven structure of the reinforcing structure 30. In this embodiment, inserting 25 the hollow non-coring needle distorts the mesh of the woven structure of the reinforcing structure 30 to allow the hollow non-coring needle to pass through the continuous wall 24 and into the chamber 28.

Alternatively, the particle is made of a hydrophilic material such as 30 polyvinylpyrrolidone, polyethylene glycol, carboxy methyl cellulose, hyaluronic acid, or the like, which expands once inside the adjustable element 22 due to the absorption of liquid that is either delivered with the particles or passes through at

least a portion of the continuous wall 24 of the adjustable element 22.

In an additional embodiment, a detectable marker 34 is embedded in the continuous wall 24 of the adjustable element 22. The detectable marker 34 allows the adjustable element 22 to be located and its shape to be visualized 5 within the tissues of a patient using any number of visualization techniques which employ electromagnetic energy as a means of locating objects within the body. In one embodiment, the detectable marker is constructed of tantalum and the visualization techniques used to visualize the adjustable element 22 are x-ray or fluoroscopy as are known in the art. In an additional embodiment, the one or 10 more reinforcing structures 30 are labeled with tantalum to allow the adjustable element 22 to be visualized using x-ray, fluoroscopy or other visualization techniques as are known in the art.

Referring now to Figures 4, 5, and 6 there is shown an alternative embodiment of the implantable device 20 further includes a tubular elongate body 36, such as a conduit, where the tubular elongate body 36 has a peripheral surface 38, a proximal end 40 and a distal end 42. The adjustable element 22 has at least one opening through the continuous wall 24 to which the peripheral surface 38 is connected to and sealed to the adjustable element 22. In one embodiment, the adjustable element 22 includes an expandable element. The 15 tubular elongate body 36 is inserted through the first opening 44 and the second opening 46 such that the distal end 42 of the elongate body 36 partially extends beyond the outer surface 32 of the adjustable element 22. The peripheral surface 38 is then sealed to the walls creating the first opening 44 and the second opening 46. In one embodiment, the peripheral surface 38 is sealed to the openings using 20 sonic welding techniques as are known in the art. In one embodiment, the adjustable element is an expandable element.

The tubular elongate body 36 further includes a first interior passageway 48 extending longitudinally in the tubular elongate body 36 from a first port 50 at the proximal end 40 to a second port 52 in fluid communication 30 with the chamber 28 of the implantable device for adjustably expanding or

contracting the adjustable element 22 by applied fluid volume introduced through the first port 50.

In an additional embodiment, the tubular elongate body 36 further includes a second interior passageway 54 extending longitudinally in the tubular elongate body 36 from a proximal opening 56 through the peripheral surface 38 positioned between the proximal end 40 and the distal end 42 to a distal opening 58 through the distal end 42 of the tubular elongate body 36. In one embodiment, the second interior passageway 54 is of sufficient diameter to receive and guide an elongate probe member for the insertion of the implantable device 20 into a human body. In an alternative embodiment, the elongate probe member is removably attached at the distal end 42 and passes outside the adjustable element 22 and along side the elongate body 36 to allow placement of the device without the need for the second interior passageway 54.

The implantable device 20 further includes a rear port element 60 coupled to the proximal end 40 of the tubular elongate body 36. In one embodiment, the rear port element 60 is coupled to the proximal end 40 of the elongate body 36 using chemical adhesives, or alternatively, using sonic welding techniques as are known in the art. In an additional embodiment, the rear port element 60 and proximal end 40 of the elongate body 36 are formed together as one piece in a polymer extrusion process or polymer casting process as are known in the art. In one embodiment, the rear port element 60 and the elongate body 36 are formed of a biocompatible material such as silicone or polyurethane elastomer.

The rear port element 60 includes a cavity 62, where the cavity 62 is in fluid communication with the first port 50 of the elongate body 36. The rear port element 60 also includes an elastic septum 64 through which the cavity 62 is accessed. The elastic septum 64 is retained in the rear port element 60 by a clamp ring 66 located around the rear port element 60. In one embodiment, the clamp ring 66 is made of a biocompatible material, such as, for example, titanium. In one embodiment, the elastic septum 64 is made of a biocompatible material, such as, for example, silicone or polyurethane.

Referring now to Figures 7 and 8, there is shown an alternative

embodiment of the implantable device 20 for treating urinary incontinence or ureteral reflux. The implantable device 20 comprises an adjustable element 100 having a continuous wall 102, including an inner surface 104 and an outer surface 106, where the inner surface 104 defines a chamber 108. The continuous wall 102 also has at least a portion of the continuous wall that is constructed of a porous polymer structure that allows the movement of water between the outer surface 106 and the inner surface 104. A hydrophilic polymer 110 is substantially encapsulated in the chamber 108, where the hydrophilic polymer 110 absorbs water. As the hydrophilic polymer 110 absorbs water, it causes the chamber 108 to expand, thus enlarging the adjustable element 100.

In one embodiment, the continuous wall 102 is intended and designed to be pierced by hollow non-coring needles on one or more occasions for adjusting the volume of the adjustable element during both the implanting of the adjustable element and during subsequent postoperative adjustment of the adjustable element. As such, the continuous wall 102 is constructed of a material that is substantially self-sealing during and after being pierced by a hollow non-coring needle to maintain fluid volume within the chamber 108 of the adjustable element, and the adjustable element expands or contracts by introducing or removing the hydrophilic polymer from the chamber.

Referring now to Figure 8, there is shown an embodiment of a portion of the continuous wall 102, where the continuous wall 102 further includes one or more reinforcing structures 120 positioned between the inner surface 104 and the outer surface 106 of the continuous wall 102. In one embodiment, the one or more reinforcing structures 120 are arranged in a mesh, including fibers in a woven structure. The fibers are constructed from the group comprising one or more of polyester, nylon, polypropylene, polytetrafluoroethylene (such as TEFLO) or other polymers having a high durometer measure or high modulus constitute the reinforcing structures.

In one embodiment, the fibers of the one or more reinforcing structures 120 are woven into a support structure that is positioned between the inner surface 104 and the outer surface 106 of the continuous wall 102. In an additional embodiment, the fibers of the one or more reinforcing structures 120

are less elastic than the continuous wall 102. The woven support structure, in one embodiment, has a loose weave configuration to allow for the support structure to expand or contract with the expansion and contraction of the continuous wall 102 of the adjustable element 100.

5 In an alternative embodiment, the fibers of the one or more reinforcing structures 120 are substantially non-elastic and are arranged in a woven or mesh configuration, where the fibers have a kinked structure that allows them to expand or contract with the expansion and contraction of the continuous wall 102 of the adjustable element 100.

10 The one or more reinforcing structures 120 provide the adjustable element 100 with reinforced structural integrity and an increased ability to retain particles within the chamber 108 of the adjustable element 100. In one embodiment, the fibers of the one or more reinforcing structures 120 woven into the support structure provide a "rip-stop" function. As an example, the woven support structure allows for rip-stop protection from tears in the continuous wall 102 due to insertion and removal of hollow non-coring needles through the continuous wall 102. In an additional embodiment, the support structure prevents the migration of particle from the chamber 108, where the particles are used to inflate the adjustable element 100. In one embodiment, the particles are prevented from migrating out of the chamber 108 due to the size of the mesh of the support structure.

15

20 In an additional embodiment, a detectable marker 122 is embedded in the continuous wall 102 of the adjustable element 100. The detectable marker 122 allows the adjustable element 100 to be located and its shape to be visualized within the tissues of a patient using any number of visualization techniques which employ electromagnetic energy as a means of locating objects within the body. In one embodiment, the detectable marker is constructed of tantalum and the visualization techniques used to visualize the adjustable element 100 are x-ray or fluoroscopy as are known in the art. In an additional embodiment, the one or more reinforcing structures 120 are labeled with tantalum to allow the adjustable element 100 to be visualized using x-ray, fluoroscopy or other visualization techniques as are known in the art.

25

30

The hydrophilic material used within the chamber 108 of the adjustable element 100 is selected from a group comprising one or more of polyvinylpyrrolidone, polyethylene glycol, carboxy methyl cellulose, or hyaluronic acid. In one embodiment, the hydrophilic polymer has a particulate structure, where the hydrophilic polymer takes the form of discrete, individual polymeric units. Additionally, the particulate structure of the hydrophilic polymer has an average diameter that is greater than an average diameter of pores of the porous polymer structure. In an additional embodiment, the porous polymer structure of the continuous wall 102 has openings that are less than or equal to 200 micrometers.

In one embodiment, the continuous wall 102 is constructed of a biocompatible resiliently elastomeric polymer or polymer blend of polyurethane, silicone, or the like. In this embodiment, the continuous wall 102 stretches as the adjustable element 100 expands or contracts to a desired size. In an alternative embodiment, the continuous wall 102 is constructed of a biocompatible non-resilient polymer or polymer blend of polyethylene, polyesterterephthalate, or high modulus polystyrene, or polyesteretherketone. In this embodiment, the continuous wall 102 of the adjustable element 100 expand to a predetermined shape. The adjustable element 100 is formed into a variety of shapes. In one embodiment, the outer surface 106 of the continuous wall 102 generally defines a spherical shape. In an alternative embodiment, the outer surface 106 of the continuous wall 102 generally defines an elongate body having semi-spherical end portions. In one embodiment, an adjustable element 102 being constructed of a biocompatible resiliently elastomeric polymer or polymer blend typically retains the same general cross-sectional shape deflated as when inflated. In an alternative embodiment, when the adjustable element 102 is constructed of a biocompatible non-resilient elastomeric polymer or polymer blend the deflated adjustable element 102 typically has a configuration in which the continuous wall 102 has a folded structure which as the adjustable element 100 is inflated changes to take on a preformed cross-sectional shape and size and/or diameter.

Referring now to Figures 9 and 10, there is shown an embodiment

of the method of implanting one embodiment of the implantable device assembly 200 of the present invention for restricting a body lumen in a patient. The implantable device assembly 200 is adapted to be surgically implanted into body tissue 202 of a patient adjacent to a body lumen for coaptating the body lumen.

5 The implantable device assembly 200 comprises an elongate probe member adapted for being inserted as a guide member into body tissue 202 to locate a portion of the obturator adjacent the body lumen to be restricted. In one embodiment, the elongate probe member is an obturator 206 having a cutting end 208. A physician, after locating the body lumen such as the urethra 23 of a
10 patient, first makes a small incision in skin of the patient 211 and inserts the obturator 206, or elongate probe member, in the body tissue to a desired location adjacent the urethra 23. This procedure is usually carried out under a local anesthetic with visual guidance, for instance by cystoscopy or fluoroscopy by the physician. The obturator 206 is of sufficient strength and rigidity to allow its
15 insertion into the tissue 202 of the patient adjacent and parallel with the urethra 23.

Referring to Figure 10, an implantable medical device 210, adapted for being surgically implanted into the tissue 202 adjacent to the body lumen, is then positioned onto the obturator 206 and advance into the tissue 202 of the patient. In one embodiment, the obturator 206 is inserted near the meatus urinarius 204 and advance through the periurethral tissue adjacent the urethra 23. In one embodiment, a detent or mark is provided on the obturator 206 which when aligned with a feature on the implantable medical device 210, such as a rear port element 60, ensures that an implantable medical device 210 is appropriately placed at the correct depth in the patient's body tissue. In an additional embodiment, the elongate body 36 of the implantable medical device 210 is available having a variety of lengths to accommodate the patient's anatomic structure so as to facilitate placement of the elastic septum on the rear port element 60 near the patient's skin. Alternatively, the elongate body 36 effective length could be made adjustable by it having a helical shape similar to that of a coiled spring.
20
25
30

While this invention has utility by effecting urethral coaptation for

both male and female patients, the mode of delivery of the device to the site makes it somewhat easier to use for females due to the anatomical differences. In one embodiment, the implantable medical device of the present invention relates to use in female patients. According to its method for use, a physician 5 will initially make a small incision at either side of the meatus, *i.e.* opening of the female urethra. This incision(s) permits an obturator, or a delivery probe member, to be inserted into the body tissue alongside of the urethra so as to define the path of later entry for the implantable device. Next, delivery of the device along the guide probe is made on either one or two opposite sides of the 10 urethra, one placement at a time. The implanted device with the expandable membrane element directed to each location is left in place, with access for adjustment of the membrane size being available through a remote elastic septum in the rear port away from the expandable membrane and located immediately under the skin of the patient.

15 Figure 10 shows one embodiment of the implantable medical device 210, where the implantable medical device 210 includes an adjustable element 22, a tubular elongate body 36, and a rear port element 60. The adjustable element 22 has a continuous wall, including an inner surface defining a chamber. The tubular elongate body 36, has a peripheral surface 38, a proximal end 40 and a distal end 44, where the peripheral surface is connected to and sealed to the adjustable element 22. The tubular elongate body includes a first interior passageway and a second interior passageway, the first interior passageway extending longitudinally in the tubular elongate body from a first port at the proximal end to a second port in fluid communication with the 20 chamber of the implantable device for adjustably expanding or contracting the adjustable element 22 by applied fluid volume introduced through the first port. 25

30 The second interior passageway also extends longitudinally in the tubular elongate body 36 from a proximal opening 56 through the peripheral surface 38 positioned between the proximal end 40 and the distal end 44 to a distal opening 58 through the distal end of the tubular elongate body 42. The second interior passageway being of sufficient diameter to receive and guide the obturator 206, or elongate probe member, for the insertion of the implantable

device into the patient's body. The rear port element 60 of the implantable medical device 210 is coupled to the proximal end 40 of the tubular elongate body 36, where the rear port element includes a cavity in fluid communication with the first port of the first interior passageway.

5 In one embodiment, once the obturator 206 has been inserted into the patient's tissue, the portion of the obturator 206 extending from the patient's body is inserted into the distal opening 58 of the second interior passageway. The implantable medical device 210 is then advance or moved along or over the obturator 206 to position the adjustable element 22 adjacent the body lumen to
10 be restricted and to position the rear port element subcutaneously. In one embodiment, the adjustable element 22 is positioned adjacent a urethra. In an additional embodiment, two or more of the implantable medical devices 220 are implanted within the body tissue adjacent a urethra. The obturator 206 is then withdrawn from the tissue of the patient by pulling the obturator 206 through the
15 proximal opening 56 of the second interior passageway, leaving the implantable medical device 210 in position.

Referring now to Figures 11, 12 and 13 there is shown one embodiment of the implantable medical device 210 implanted in the tissue of a patient for restricting a body lumen. In one embodiment, the body lumen is the
20 urethra 23 and the implantable medical device 210 has been implanted in the periurethral tissue of the patient.

After the implantable medical device 210 has been advanced over the obturator 206, or elongate probe member, so that the contracted adjustable element 22 is in the desired position adjacent to the urethra 23, the urethra 23 is
25 restricted to a desired degree by piercing the elastic septum with a needle of a syringe and injecting a flowable material through the first interior passageway into the adjustable element 22. The physician may determine the desired degree of restriction of urethra 23 by means such as infusing fluid through the urethra 23 past the restriction and measuring the back pressure. As illustrated by Figure 11
30 the source of flowable material is usually a syringe 220 with a hollow non-coring needle 222 used to pierce the elastic septum, however alternate fluid containers with means for making a reversible connection to implantable medical device

210 could be used. The flowable material may be, for example, a saline solution, a flowable gel, or a slurry of particles in a liquid carrier. It may be advantageous to make the flowable material radiopaque so that the degree of membrane inflation may be viewed by x-ray.

5 An alternative method of delivery of the implantable medical device 210 could be to first withdraw obturator 206, or elongate probe member, from the body tissue and then inflate adjustable element 22. A further alternative would be to first place the implantable medical device 210 over the obturator 206, or elongate probe member, outside the body and then insert them both into 10 the body tissue as a unit. To facilitate this latter procedure, it may be desirable that there be some friction between the obturator 206, or elongate probe member, and the second interior passageway.

15 After the implantable device has been properly positioned with the adjustable element 22 located near the urethra 23 and the elastic septum in rear port element 60 located near the skin, the implantable medical device 210 is injected with a flowable material from the syringe 220. Once filling of the adjustable element 22 is complete, the obturator 206, or elongate probe member, is withdrawn from the implantable medical device 210 leaving the adjustable 20 implantable medical device in the body tissue. Then the skin incision is closed over the rear port element 60 by means such as a suture 230 as shown in Figure 12.

25 In an additional embodiment, the presence of the port located near the surface of the patient's skin affords the additional advantage of allowing the device to be easily removed through a small incision in the skin if, for instance, it was to become infected or malfunction, whereas the prior art devices would require major surgery. Furthermore, the presence of the elongate body and the rear port of the implantable device left in the device delivery tract will serve to prevent backward migration of the expandable element along the tract, a problem which has been noted with prior art devices. In an additional embodiment, twists 30 or coils in the implanted device elongate body may permit the body tissue to grow around it and further anchor the implantable device in the patient's body.

As described, one feature of this invention relates to the

adjustability of the adjustable element 22 postoperatively. This adjustability is effected because the elastic septum is located remote from the adjustable element 22 but near and under the patient's skin. The rear port element 60 and the elastic septum are located by, for instance, manual palpation of the skin region and the needle of the syringe is inserted through the skin and septum so as to add or remove material from the adjustable element 22, thus increasing or decreasing the restriction of the body lumen.

Referring to Figure 13, there is shown one embodiment of the adjustable element 22 implanted adjacent a body lumen. The adjustable element 22 is shown in an expanded state, such that it increases both localized tissue volume and passive occlusive pressure upon the body lumen. In one embodiment, the body lumen is the urethra 23 of a patient, and the patient's incontinence is treated by positioning one or more of the adjustable elements 22 of the implantable medical devices 210 adjacent the urethra 23 so as to allow the physician to adjust liquid flow resistance in the urethra 23. This is accomplished by the implantable devices coapting the patient's urethra as previously described so as to maintain a transverse cleft or slit structure of the collapsed urethra and thereby provide sufficient flow resistance, so that enough pressure is provided to maintain continence, but not so much pressure as to prevent the patient from consciously urinating.

In one embodiment, two of the devices are implanted on opposite sides of the urethra so as to effect a balanced urethral coaptation and resistance. If after implantation inflation of the expandable membrane is excessive, thereby creating a disproportionate urethral resistance by obstructing the patient and causing a bladder pressure higher than normal during voiding, damage to the bladder and kidney may ensue. Thus, a post-operative membrane size adjustment is available to reduce the patient's bladder pressure during voiding and maintain intravesical pressure within normal limits. In one embodiment, two individual devices with individual septums are implanted on opposite sides of the urethra. Alternatively, the device may be so configured to have one septum serve both expandable membrane elements. Therefore, the present invention allows a more normal voiding process while maintaining continence in

the patient. This post-operative adjustment feature promotes normal voiding patterns for the patient, and appropriate vesicourethral pressure during voiding. In one embodiment, post-operative adjustment is done in a semi vertical or horizontal position with the bladder full after anesthesia is resolved and edema is minimal.

Referring now to Figures 14 and 15 there is shown embodiments of postoperatively adjusting an implanted adjustable element 22. The adjustable element 22 having been implanted adjacent a body lumen within a patient, is first located within the tissues of the patient. In one embodiment, locating the adjustable element 22 is accomplished using fluoroscopy, x-ray, or ultrasound visualization techniques as are known in the art. Once the adjustable element has been located within the tissue of the patient, the physician then proceeds to establish fluid communication with the adjustable element 22. In Figure 14 one adjustable element 22 having generally a spherical configuration is shown positioned adjacent a body lumen, such as a urethra or a ureteral orifice, of a patient. Alternatively, Figure 15 shows an additional embodiment where two adjustable elements 22 each having a configuration that is generally an elongate body having semi-spherical end portions.

In one embodiment of making an adjustment, fluid communication is established with the adjustable element by first inserting a catheter structure 300 into the urethra of the patient. In one embodiment, the catheter structure 300 has an elongate body 302 proximal end 304 and a distal end 306. The catheter structure 300 includes a fluid passageway extending longitudinally within the catheter structure 300 from an inlet port 308 at the proximal end 304 to a outlet port 310 at the distal end 306. In one embodiment, a hollow non-coring needle 312 is coupled to the outlet port 310. In an additional embodiment, the fluid passageway housed within the elongate body 302 of the catheter structure 300 moves longitudinally within the elongate body 302 to allow the hollow non-coring needle 312 coupled to the outlet port 310 to, in one position, extend beyond the distal end 306 of the elongate body 302; and in another position to be housed completely within the elongate body 302 of the catheter structure 300.

In an additional embodiment, the path of the hollow non-coring needle 312 as it is extended beyond the distal end 306 of the catheter structure 300 deflects away from a plane that is generally parallel with the longitudinal axis of the elongate body 302 of the catheter structure 300. In one embodiment, 5 this allows the hollow non-coring needle 312 to penetrate through the urethral tissue and into the continuous wall of the adjustable element 22. The hollow non-coring needle 312 is then advanced into the chamber of the adjustable element 22 at which point the physician adjusts the volume of the adjustable element 22. In one embodiment, the volume of the adjustable element is adjusted by passing fluid and/or particles through the hollow non-coring needle to adjustably contract or expand the adjustable element 22 due to fluid volume 10 introduced into the chamber.

Figure 15 shows an alternative embodiment for adjusting the adjustable element 22, where the catheter structure 300 is first inserted through the tissues of the patient. The distal end of the catheter structure 300 is then 15 aligned with the outside surface of the adjustable element 22 and the hollow non-coring needle 312 is advanced through the continuous wall of the adjustable element and into the chamber to allow the adjustable element to be either expanded or contracted by passing fluid, particles and/or hydrophilic polymer 20 through the hollow non-coring needle 312 as previously described.

In an additional embodiment, the elongate body 302 of the catheter structure 300 acts as a needle stop to limit the depth to which the needle is allowed to penetrate the implanted adjustable element 22. In an additional embodiment, the outer surface 32 of the adjustable element is secured to the catheter structure 300 during the insertion of the hollow non-coring needle 312 into the adjustable element 22. In one embodiment, a suction passageway extends longitudinally 25 within the elongate body 302 to allow the distal end 306 of the catheter structure 300 to be secured to the outer surface 32 of the adjustable element 22 by a negative or vacuum pressure applied through the suction passageway. Once the 30 catheter structure 300 is secured to the adjustable element 22, the hollow non-coring needle 312 is extended from the catheter structure 300 to pierce the

continuous wall of the adjustable element 22 and allow for its volumetric adjustment.

WHAT IS CLAIMED:

1. An expandable device, comprising:
5 a pressurizable adjustable element, attached to an elongate conduit element near its forward end, said conduit element including a rear port portion and having a first passageway connecting said rear port portion to said adjustable element, said adjustable element expandable to enlarged shapes by addition of a flowable material provided into said rear port portion.
- 10 2. The device according to claim 1, wherein the expandable device is adapted for implantation within body tissue with the adjustable element adjacent a body lumen to provide volume to the body tissue for adjustable coaptation of the body lumen.
- 15 3. The device according to any of the preceding claims, wherein said rear port portion is adapted for providing fluid communication between the implantable device and an external source during adjustment and for automatically sealing the flowable material in the implantable device upon removal of the external source.
- 20 4. The device according to any of the preceding claims, wherein said rear port portion comprises an elastic septum.
- 25 5. The device according to any of the preceding claims, wherein said elongate conduit has a second elongate passageway extending from the conduit forward tip end to a location rearward from said adjustable element.
- 30 6. The device according to any of the preceding claims, wherein said adjustable element is attached onto said elongate conduit element by a material comprising an adhesive material.

7. The device according to any of the preceding claims, wherein said elongated conduit element permits subcutaneous positioning of the rear port portion.
- 5 8. The device according to any of the preceding claims, wherein the implantable device is constructed using a bio compatible material such as polyurethane or silicone.
- 10 9. The device according to any of the preceding claims, wherein the rear port portion comprises a compression ring for maintaining a seal of the rear port portion.
- 15 10. The device according to any of the preceding claims, further comprising an external source containing a flowable material and adapted for connection to the rear port portion of said implantable device, whereby a flowable material from said external source can be introduced through the rear port portion and through the first passageway of said implantable device so as to expand the forward adjustable element adjacent a body lumen to at least partially and adjustably restrict the lumen.
- 20 11. The device according to any of the preceding claims, further comprising a second passageway adapted for receiving an elongate probe member.
- 25 12. The device according to claim 11, further comprising an elongate probe member adapted for being inserted into tissue adjacent a body lumen of a patient.
13. The device according to claim 11 or 12, wherein said probe member comprises a stiff elongate rod having a pointed forward end.
- 30 14. The device according to claim 11 or 12, wherein said probe member comprises a flexible guidewire.

15. The device according to any of the preceding claims, wherein said rear port portion contains an elastic septum and said device is adjusted using a syringe having a forward facing needle whereby said needle may be sealingly inserted in said septum and a flowable material injected from said syringe through the first passageway to expand the adjustable element.

5

16. A method, comprising the steps of:
guiding an elongate implantable device into body tissue of a patient to a location adjacent a body lumen to be restricted using an elongate probe member, the elongate implantable device having an adjustable element located at its forward end and having a port portion provided at its rearward end, so that the adjustable element is positioned adjacent to the body lumen; and
providing a flowable material from a source into the port portion, so as to expand the adjustable element to at least partially restrict the body lumen.

10

15

17. The method according to claim 16, further comprising the steps of:
withdrawing the elongate probe member from the patient's body;
positioning the port portion of said elongate implantable device inside the patient's body tissue near the surface of the skin; and
closing an opening made in the patient's skin over the port portion.

20

18. The method according to claim 16 or 17, wherein the step of providing a flowable material includes injecting one or more of a saline liquid solution, a gel, or a slurry of particles in a fluid carrier.

25

19. The method according to any one of claims 16 to 18, wherein the step of providing a flowable material includes injecting a radiopaque material to facilitate fluoroscopic visualization.

30

20. The method according to any one of claims 16 to 19, wherein the elongate probe member and implantable device are positioned at a location adjacent the

urethra of a patient.

21. The method according to any one of claims 16 to 20, including placing an implantable device along two opposite sides of the urethra of a patient.

5

22. The method according to any one of claims 16 to 21, wherein the implantable device is guided over the elongate probe member.

10 23. The method according to any one of claims 16 to 21, wherein the implantable device and elongate probe member are inserted as a unit into body tissue.

24. The method according to any one of claims 16 to 23, wherein the implantable device is positioned using visual guidance.

15

25. The method according to any one of claims 16 to 24, wherein the implantable device is positioned using fluoroscopy.

20
25

26. The method according to any one of claims 16 to 25, further comprising the step of:

increasing restriction of the body lumen by adding flowable material to the implantable device.

25

27. The method according to any one of claims 16 to 25, further comprising the step of:

decreasing restriction of the body lumen by removing flowable material from the implantable device.

30

28. The method according to any one of claims 16 to 27, wherein the step of providing a flowable material from a source into the port portion comprises the step of:

injecting the flowable material into a septum of the port portion using a hyperdermic needle.

29. The method according to any one of claims 16 to 28, further comprising
5 the step of:

expanding the adjustable element prior to withdrawal of the elongated probe member.

30. A method, comprising the steps of:
10 locating a region of a patient's skin covering a rear port portion of an implantable device;

inserting a hypodermic needle into the region for communication of a flowable material with the rear port portion; and

15 adding or subtracting flowable material to adjust inflation of an adjustable element of the implantable device to affect coaptation of a body lumen.

31. The method according to claim 30, wherein the step of inserting comprises the step of inserting the hypodermic needle into a septum.

20 32. The method according to any one of claims 30 and 31, wherein the implantable device is postoperatively adjusted.

33. A device, comprising:
an adjustable element including a membrane enclosing a volume, the
25 adjustable element adapted to contain a flowable material, the membrane adapted to self-sealing of punctures, and
wherein the adjustable element expands upon introduction of flowable material into the membrane, and where the adjustable element is adjustable in size by adjusting an amount of flowable material in the membrane.

30 34. The device according to claim 33, wherein the device is shaped to provide

increased tissue volume adjacent a body lumen and is adjustable to control coaptation of a body lumen by introduction or withdrawal of flowable material.

35. The device according to any one of claims 33 to 34, where the membrane
5 is made of a resilient material.

36. The device according to any one of claims 33 to 34, where the adjustable element expands to a predetermined shape.

10 37. The device according to any one of claims 33 to 36, where the membrane includes a mesh.

38. The device according to any one of claims 33 to 37, where a self-sealing material is applied to an inner surface of the membrane.

15 39. The device according to any one of claims 33 to 38, the membrane comprising one or more reinforcing structures.

20 40. The device according to any one of claims 33 to 39, where the membrane comprises a porous polymer structure permeable to a fluid, and a hydrophilic polymer substantially encapsulated in the membrane, where the hydrophilic polymer absorbs fluid to expand the adjustable element.

25 41. The device according to any one of claims 33 to 40, where the adjustable element expands or contracts by introducing or removing the hydrophilic polymer from the membrane.

30 42. The device according to any one of claims 40 to 41, where the hydrophilic polymer has a particulate structure having an average diameter that is greater than an average diameter of pores of the porous polymer structure.

43. The device according to claim 37, where the flowable material introduced into the membrane includes particles having diameters greater than openings of the mesh.

5 44. The device according to any one of claims 33 to 43, where the membrane is constructed of a biocompatible resiliently elastomeric polymer or polymer blend.

10 45. The device according to any one of claims 33 to 44, where the adjustable element has an outer surface generally defining a sphere.

15 46. The device according to any one of claims 33 to 45, where the adjustable element has an outer surface generally defining an elongate body having semi-spherical end portions.

20 47. The device according to any one of claims 33 to 46, where a detectable marker is embedded in the membrane of the adjustable element.

25 48. The device according to any one of claims 33 to 47, wherein the membrane is connected to a conduit at a first end, the conduit having a second end connected to a port, providing fluid communication between the port and the membrane, such that flowable material introduced into the port is passed into the membrane .

30 49. The device according to claim 48, where the conduit comprises a passageway extending longitudinally and of diameter to receive an elongate probe member.

50. The device according to any one of claims 48 to 49, where the port is adapted for sealing to contain flowable material within the implantable device.

51. The device according to any one of claims 48 to 50, where the port comprises a septum.

52. A device assembly adapted for being surgically implanted into body tissue of a patient adjacent a body lumen for collapsing the body lumen, the assembly comprising;

10 an implantable device adapted for being surgically implanted into the tissue adjacent to the body lumen, the implantable device including an adjustable element, a tubular elongate body, and a rear port element;

15 the adjustable element having a continuous wall, including an inner surface defining a chamber;

20 the tubular elongate body, having a peripheral surface, a proximal end and a distal end, where the peripheral surface is connected to and sealed to the adjustable element, the tubular elongate body including a first interior passageway and a second interior passageway, the first interior passageway extending longitudinally in the tubular elongate body from a first port at the proximal end to a second port in fluid communication with the chamber of the implantable device for adjustably expanding or contracting the adjustable element by applied fluid volume introduced through the first port, and the second interior passageway extending longitudinally in the tubular elongate body from a proximal opening through the peripheral surface positioned between the proximal and the distal end to a distal opening through the distal end of the tubular elongate body, the second interior passageway being of sufficient diameter to receive and guide an obturator for the insertion of the implantable device into a human body;

25 the rear port element coupled to the proximal end of the tubular elongate body, the rear port element including a cavity in fluid communication with the first port of the first interior passageway; and

30 a fluid source adapted to be releasably connected to the rear port element, where the adjustable element expands or contracts due to fluid

volume introduced into the cavity of the rear port element from the fluid source to at least partially and adjustably restrict the body lumen.

53. The implantable device assembly of claim 52, where the rear port element
5 has an elastic septum and the fluid source is a syringe having a hollow
non-coring needle, where the hollow non-coring needle is inserted through the
elastic septum and fluid from the syringe is introduced into or extracted from the
cavity in the rear port element to expand or contract the adjustable element.




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 2




FIG. 3




FIG. 4

6/12




FIG. 5




FIG. 6




FIG. 7






FIG. 8






FIG. 11




FIG. 13




FIG. 12

11/12




FIG. 14




FIG. 15

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/US 98/12368

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61F2/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61F A61B A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 112 303 A (PUDENZ ROBERT H ET AL) 12 May 1992	1-3,6,8, 10,15, 33-36, 39,45,47
A	see the whole document	5,7,9, 52,53
X	US 4 817 637 A (HILLEGASS DONALD V ET AL) 4 April 1989	1-4,7,8, 33-36, 45,48, 50,51
A	see column 3, line 15 - column 4, line 32; figures	15,52,53
	—	-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "8" document member of the same patent family

Date of the actual completion of the International search

1 October 1998

Date of mailing of the International search report

09.10.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax. (+31-70) 340-3016

Authorized officer

Neumann, E

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 98/12368

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 637 074 A (ANDINO RAFAEL V ET AL) 10 June 1997 see column 13, line 35 - column 14, line 17; figures see column 16, line 63 - column 17, line 31 see column 21, line 31 - line 40	1,2,5-8, 10,15
A		3,9, 33-36, 40,41, 45,52,53
X	WO 91 00069 A (RULL JOHANN) 10 January 1991 see page 5, last paragraph - page 6, paragraph 1; figures	33-36, 38,46
A		1-3,8, 15,52,53

International application No.
PCT/US-98/12368

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 16-32 because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal ref Application No

PCT/US 98/12368

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5112303	A	12-05-1992	NONE		
US 4817637	A	04-04-1989	NONE		
US 5637074	A	10-06-1997	US 5437603 A	01-08-1995	
			CA 2149140 A	30-03-1995	
			EP 0678009 A	25-10-1995	
			JP 8503159 T	09-04-1996	
			WO 9508303 A	30-03-1995	
WO 9100069	A	10-01-1991	DE 3921120 A	03-01-1991	
			AT 118162 T	17-02-1995	
			DE 59008441 D	23-03-1991	
			EP 0479881 A	15-04-1991	
			JP 4506309 T	05-11-1991	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)